A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. 12-Month Outcomes From the ENDEAVOR IV Trial

Martin B. Leon, Laura Mauri, Jeffrey J. Popma, Donald E. Cutlip, Eugenia Nikolsky, Charles O'Shaughnessy, Paul A. Overlie, Brent T. McLaurin, Stuart L. Solomon, John S. Douglas, Michael W. Ball, Ronald P. Caputo, Ash Jain, Thaddeus R. Tolleson, Bernard M. Reen, Ajay J. Kirtane, Peter J. Fitzgerald, Kweli Thompson, David E. Kandzari

Research output: Contribution to journalArticle

205 Scopus citations

Fingerprint Dive into the research topics of 'A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. 12-Month Outcomes From the ENDEAVOR IV Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences